Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1648156 Immunology Correction Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study Wang Wenhua 1 2 † Wang Bingyi 1 2 † Sun Yifei 1 2 Qiu Lihua 1 2 Qian Zhengzi 1 2 Zhou Shiyong 1 2 Song Zheng 1 2 Li Wei 1 2 Zhang Xudong 3 * Li Lanfang 1 2 * Wang Xianhuo 1 2 * Zhang Huilai 1 2 * 1 State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China 2 Key Laboratory of Cancer Prevention and Therapy, The Sino-United States Center for Lymphoma and Leukemia Research, Tianjin, China 3 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Xudong Zhang, fcczhangxd@zzu.edu.cn; Lanfang Li, lilanfangmeng@163.com; Xianhuo Wang, tjzlyy_xianhuow@163.com; Huilai Zhang, zhlwgq@126.com

†These authors have contributed equally to this work

 04 09 2025 2025 16 1648156 16 06 2025 28 08 2025 Copyright © 2025 Wang, Wang, Sun, Qiu, Qian, Zhou, Song, Li, Zhang, Li, Wang and Zhang. 2025 Wang, Wang, Sun, Qiu, Qian, Zhou, Song, Li, Zhang, Li, Wang and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study By Wang W, Wang B, Sun Y, Qiu L, Qian Z, Zhou S, Song Z, Li W, Zhang X, Li L, Wang X and Zhang H (2025) Front. Immunol. 16:1579483. doi: 10.3389/fimmu.2025.1579483 central nervous system lymphoma ibrutinib retrospective methotrexate section-in-acceptance Cancer Immunity and Immunotherapy

In the published article, there was an error in the author list, and author “Xudong Zhang” was erroneously excluded. The corrected author list appears below.

“Wenhua Wang1,2†, Bingyi Wang1,2†, Yifei Sun1,2, Lihua Qiu1,2, Zhengzi Qian1,2, Shiyong Zhou1,2, Zheng Song1,2, Wei Li1,2, Xudong Zhang3*, Lanfang Li1,2*, Xianhuo Wang1,2* and Huilai Zhang1,2*”

They should also have the affiliation: “3Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China”.

In the published article, there was an error in the Copyright statement. The statement was incorrectly written as “Copyright © 2025 Wang, Wang, Sun, Qiu, Qian, Zhou, Song, Li, Li, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.” The corrected statement is “Copyright © 2025 Wang, Wang, Sun, Qiu, Qian, Zhou, Song, Li, Zhang, Li, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.”

In the published article, there was also several errors in the text. “Some patient data were obtained from the First Affiliated Hospital of Zhengzhou University, and due to carelessness, we did not mention this in the article”.

A correction has been made to Materials and methods, Patients and treatment, Paragraph 1. This sentence previously stated:

“From March 2013 to October 2022, 88 newly diagnosed PCNSL patients from Tianjin Medical University Cancer Institute & Hospital (TMUCIH) were retrospectively enrolled and analyzed.”

The corrected sentence appears below:

“From March 2013 to October 2022, 88 newly diagnosed PCNSL patients from Tianjin Medical University Cancer Institute & Hospital (TMUCIH) and the First Affiliated Hospital of Zhengzhou University were retrospectively enrolled and analyzed.”

The study was also approved by the institutional review board of the Tianjin Medical University Cancer Institute & Hospital and the First Affiliated Hospital of Zhengzhou University. However, due to carelessness, only the former was mentioned in the article.

A correction has been made to Materials and methods, Patients and treatment, Paragraph 1. This sentence previously stated:

“The study was approved by the institutional review board of the Tianjin Medical University Cancer Institute and Hospital.”

The corrected sentence appears below:

“The study was approved by the institutional review board of the Tianjin Medical University Cancer Institute & Hospital and the First Affiliated Hospital of Zhengzhou University.”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.